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Abstract
JC virus is a human polyomavirus that infects the majority of people without apparent symptoms in healthy subjects and it
is the causative agent of progressive multifocal leucoencephalopathy (PML), a disorder following lytic infection of
oligodendrocytes that mainly manifests itself under immunosuppressive conditions. A hallmark for JC virus isolated from
PML-brain is the presence of rearrangements in the non-coding control region (NCCR) interspersed between the early and
late genes on the viral genome. Such rearrangements are believed to originate from the archetype JC virus which is shed in
urine by healthy subjects and PML patients. We applied next generation sequencing to explore the non-coding control
region variability in urine of healthy subjects in search for JC virus quasispecies and rearrangements reminiscent of PML. For
61 viral shedders (out of a total of 254 healthy subjects) non-coding control region DNA and VP1 (major capsid protein)
coding sequences were initially obtained by Sanger sequencing. Deletions between 1 and 28 nucleotides long appeared in
,24.5% of the NCCR sequences while insertions were only detected in ,3.3% of the samples. 454 pyrosequencing was
applied on a subset of 54 urine samples demonstrating the existence of JC virus quasispecies in four subjects (,7.4%).
Hence, our results indicate that JC virus DNA in urine is not always restricted to one unique virus variant, but can be a
mixture of naturally occurring variants (quasispecies) reflecting the susceptibility of the non-coding control region for
genomic rearrangements in healthy individuals. Our findings pave the way to explore the presence of viral quasispecies and
the altered viral tropism that might go along with it as a potential risk factor for opportunistic secondary infections such as
PML.
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Introduction
Human polyoma viruses (HPyVs) are non-enveloped DNA
viruses with a ,5 kilobase pair circular, double-stranded DNA
genome. Several members of this virus family are associated with
human pathologies. JC virus (JCV) infection can result in a severe
clinical outcome i.e. progressive multifocal leucoencephalopathy
(PML), an often fatal neurological disorder resulting from a
demyelination process after lytic infection of oligodendrocytes
[1,2]. PML occurs predominantly in patients suffering from
immune deficiencies (e.g. HIV-patients) or patients undergoing
immuno-modulatory therapies. For instance, PML-cases have
been reported for patients treated with immuno-modulatory
monoclonal antibodies such as natalizumab and rituximab [3,4].
BK virus (BKV), the polyomavirus most closely related to JCV,
has been shown to be involved in nephropathy after kidney
transplant and may also be an opportunistic pathogen of the
central nervous system [5,6,7]. Also JCV has been associated with
nephropathy [8]. More recently, other human polyoma viruses
such as Merkel cell polyomavirus (MCV) and TSPyV have also
raised interest as oncogenic viruses [9,10,11].
The genome of JC virus encodes both structural and regulatory
proteins [12]. Small t-antigen (stAg) and large T-antigen (LTAg)
are early expressed regulatory proteins resulting from alternative
splicing of the same primary transcript and play a key role in viral
replication [13,14]. Late genes encode the viral capsid proteins
VP1, VP2, and VP3, as well as agnoprotein, another regulatory
protein. Expression of early and late genes is regulated by a bi-
directional non-coding control region (NCCR) which is positioned
on the genome between the coding parts of the early and late
genes [12]. This control region carries the viral origin of
replication (ori) immediately followed by DNA sequence motifs
recognized by host transcription factors. As such the NCCR is a
key determinant in regulating viral replication and early and late
transcription events in host cells permissive for JCV infection, as
has been experimentally shown in several in vitro cell studies
[15,16,17].
Within an infected host at least two main JC virus variants can
exist that differ predominantly in the organization of the NCCR.
In the current view, following infection a non-pathogenic form of
JC virus can persist in a variety of cell types including, but not
limited to, kidney epithelial cells, tonsils and B cell precursors in
bone marrow [18]. Primary infection in general occurs without
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apparent symptoms. Based on the prevalence of anti JCV-
antibodies directed against the major capsid protein VP1, it has
been estimated that the vast majority of humans have experienced
JC virus infection, often already during childhood [18]. A
subpopulation of infected people also shed JCV DNA in their
urine (viruria). The naturally occurring JCV variant found in urine
of both healthy individuals as well as PML-patients is known as the
archetype JC virus and is characterized by a typical, well-
conserved architecture of the non-coding control region i.e. it is
build up of a defined sequence of DNA motifs referred to as
domain a to f [19,20]. JC virus isolated from brain and
cerebrospinal fluid (CSF) from patients diagnosed with PML
typically carries multiple genomic rearrangements in the NCCR
[17,21] that are believed to have evolved from the archetype virus
by deletions and duplications [19] and that can be very hyper
variable between individual PML-cases [21].
Since archetype JC virus has not been associated with PML
NCCR rearrangements (i.e. insertions and deletions) might be a
driving force for viral replication and gene transcription in glial
cell types ultimately triggering the lytic phase as suggested by
previous reports [17,22]. Although single nucleotide differences
between NCCR sequences are not uncommon, their functional
impact remains largely unknown [17,21,23]. Hence, since the
accumulation of DNA rearrangements in the NCCR might alter
JCV tropism by changing DNA binding sites for cellular
transcription factors in cells permissive for infection [15,24]
investigating the naturally occurring variability in the non-coding
control region of JC virus and the presence of potential
quasispecies seems of particular interest. In addition, upon
potential dissemination of the virus within the host, these
rearrangements might support viral replication in cell types other
than the primary sites of infection.
As a first step in this thinking, we set up a detailed analysis of the
presence of genomic rearrangements and nucleotide variability in
the non-coding control region of JC virus DNA as it is isolated
from urine of healthy subjects. As a gold standard, Sanger
sequencing was used to determine the NCCR sequence and the
VP1 coding sequence for the examined samples. Next, 454
amplicon sequencing was applied on a subset of 54 samples to
study in detail the presence of potential JCV quasispecies. Our
data provide evidence for the existence of JC virus quasispecies
within naturally infected hosts and shed light on the degree of
variability present in the JC virus NCCR DNA.
Materials and Methods
Ethics statement
The Ethics Committee [‘‘Commissie voor Medische Ethiek -
ZiekenhuisNetwerk Antwerpen (ZNA) and the Ethics committee
University Hospital Antwerp] approved the Protocols, and
Informed consents, which were signed by all subjects.
Healthy subject samples
A total of 254 healthy subjects (HSs) were selected in Belgium
for this study: 135 women and 119 men with an age ranging from
19 up to 66 years (median 42 y, average 42.2 y, 25% percentile
35 y, 75% percentile 50 y). 36 of these HSs donated one or more
consecutive urine samples over a time interval of one year. Urine
samples were collected and stored at 280uC until further
processing.
JC virus viral load assay
DNA was extracted from 200 ml or 1 ml urine aliquots using the
NucliSENSH easyMAGH reagents and platform (Biome´rieux).
DNA was eluted in 25 ml final volume. The presence of JC virus
DNA was determined by quantitative Polymerase Chain Reaction
(qPCR) utilizing a previously described primer set (i.e. JCT-1,
JCT-2 ) and a FAM/TAMRA labeled internal probe (JCT-1.1)
designed to amplify a JC virus large T (LTAg) gene fragment [25].
To quantify the viral load the targeted LTAg gene fragment was
subcloned into a pMA backbone (Life Technologies). A 10-fold
serial dilution of linearized plasmid DNA was prepared covering a
dynamic range of 10 to 108 calculated copy numbers per 5 ml.
Another plasmid carrying the homologuous BK virus LTAg gene
fragment was prepared similarly and included as negative control
plasmid. For each sample a 15 ml pre-PCR mixture was prepared
containing: 10 ml LightCyclerH Probe master (26) (Roche),
0.06 ml primer JCT-1 (100 mM), 0.06 ml primer JCT-2
(100 mM), 0.04 ml probe JCT-1.1 (100 mM) and 4.84 ml PCR
grade water. 5 ml of DNA extracted from urine, plasmid DNA or
PCR grade water (i.e. no template control) was added. Samples
were run in duplicate on the BioRad CFX 96 thermocycler with
following cycling conditions: 95uC for 5 min, followed by 40 cycles
of 95uC for 10 s, 60uC for 10 s and 72uC for 10 s. qPCR data
were analyzed with the BioRad CFX ManagerTM software v2.1.
and the JC virus VL calculated and expressed as log copies per ml
urine.
Sanger sequencing of JC virus non-coding control region
and VP1 coding sequence
Viral DNA was extracted from urine as described above and
used as template for outer PCR using Phusion high fidelity master
mix (26) (New England Biolabs) and template specific primers: [59
gattcctccctattcagcactttg 39 (Fwd primer) and 59 tccactccaggttttac-
taa 39 (Rev primer); JCV NCCR] and [59 cctcaatggatgttgccttt 39
(Fwd primer) and 59 aaaaccaaagacccctc 39 (Rev primer); JCV VP1
coding sequence]. Cycling conditions for PCR were: 98uC for
30 seconds followed by 40 cycles of 98uC for 10 sec, 60uC for
20 sec and 72uC for 20 sec and a final step at 72uC for 5 min.
Generated PCR products were subsequently used as template for
sequencing PCR using BigDye termination sequencing reagents
(Applied Biosystems) and sequencing primers: [59 ctattcag-
cactttgtccattttagc 39 (Fwd primer NCCR) and 59 ggttttactaactttca-
cagaagcct 39 (Rev primer NCCR] or [59ctttacttttagggttgtacgggac
39 (Fwd primer1 VP1); 59 tgaggatctaacctgtggaa 39 (Fwd primer2
VP1); 59ctcccccaaaataactgcaact 39 (Rev primer1 VP1) and 59
tcctctccactgctggga 39 (Rev primer2 VP1). Sequencing PCR was
run as follows: 96uC for 1 min followed by 35 cycles of 96uC for
10 sec, 50uC for 5 sec and 60uC for 4 min. Samples were purified
[DyeEx 2.0 Spin kit (Qiagen)] and run on the 37306l DNA
Analyzer (Applied Biosystems). DNA sequences were analyzed
with the SeqScape v2.5 software. Non-coding control region DNA
sequences harboring rearrangements were submitted to EMBL/
GenBank (accession numbers HF955438 to HF955450).
Phylogenetic analysis of HS samples
Full length VP1 coding sequences (1065 bp) obtained for HS
samples (n = 61) were used for phylogenetic analysis. All sequences
were first compared to VP1 coding sequences retrieved from JC
virus genotype reference strains [26] in a multiple sequence
alignment using clustalW2 (http://www.ebi.ac.uk/Tools/msa/
clustalw2/). Data were further processed with the MEGA 5.05
software to generate a phylogenetic tree using Neighbour Joining
method. The VP1 coding sequence of JCV genotype 6 was used to
root the tree. All different VP1 coding sequences have been
submitted to EMBL/GenBank and have accession numbers
HF955451 to HF955498.
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454 amplicon sequencing on GS Junior platform
Control plasmids included in the study. An archetype JC
virus non-coding control region DNA sequence (CY isolate, NCBI
acc.nr. AB038249) was subcloned into the pMA backbone and
used as template for PCR amplification. A similar plasmid, but in
which a predefined 66 base pairs (bps) deletion corresponding to
domain d of the JCV NCCR was introduced, was also generated.
XL gold ultracompetent E. coli cells were transformed with both
plasmids according to standard procedures and single isolated
colonies were cultured overnight at 37uC in 3 ml LB-medium
under selection of 100 mg/ml ampicilline. Plasmid DNA was
prepared using the Qiaprep Spin Miniprep kit (Qiagen) following
the manufacturer’s instructions and used as template in control
PCR experiments.
Amplification of JC virus non-coding control region
DNA. The ‘‘Fusion’’ primer concept was developed by Roche
as part of the amplicon 454 sequencing protocol. The 59 end of
both forward and reverse ‘‘Fusion’’ primers is a 25-mer dictated by
the requirements for the 454 sequencing system (primer A and
primer B, respectively; see guidelines for amplicon experimental
design, Roche) followed by the sequence key ‘‘TCAG’’ and a
multiplex identifier sequence (MID) for sample identification. The
39 portion of the primers consists of target-specific sequences.
Here, we designed Fusion primers to amplify a ,483 bp DNA
fragment including the JC virus NCCR. The 39end specific
sequences were: 59 gattcctccctattcagcactttg 39 (Fwd primer) and 59
tccactccaggttttactaa 39 (Rev primer). All primers were synthesized
at IDT Technologies (Belgium).
PCR was performed on both control plasmid DNA and on viral
DNA from urine. All PCRs were run in triplicate and triplicates
were pooled afterwards. For each sample a PCR pre-mix was
prepared: 10 ml of Phusion high fidelity master mix (26) (New
England Biolabs), 1 ml forward Fusion primer (10 mM), 1 ml
reverse Fusion primer (10 mM) and 6 ml of PCR-grade water. 2 ml
of plasmid DNA preparation (i.e. ,100 000 calculated plasmid
copies) or 2 ml of extracted viral DNA was used as template (i.e.
20 ml final PCR volume). PCR was run under the following
cycling conditions: 98uC for 30 seconds followed by 40 cycles of
98uC for 10sec, 60uC for 20 sec and 72uC for 20 sec and a final
step at 72uC for 5 min. DNA amplicons were analyzed by agarose
gel electrophoresis (pre stained 1.2% e-gel, Invitrogen), purified
with AMPure XP beads (Agencourt) according to the manufac-
turer9s guidelines and eluted in low (10%) TE buffer. DNA was
quantified using the Quant-iT picogreen assay kit (Invitrogen).
Integrity of the DNA was confirmed on the Bioanalyzer 2100
(Agilent).
Basic amplicon sequencing on Roche GS-Junior platform
and data analysis. Equimolar amounts of purified JC virus
NCCR amplicons were pooled and sequenced on the GS Junior
platform. 454 sequencing was performed at VIB Nucleomics core
[http://www.nucleomics.be/, Leuven, Belgium]. All retrieved
DNA sequences were subject to quality assessment. DNA
sequences with high quality and covering the full JC virus NCCR
were mapped onto the reference sequence (i.e. NCCR from CY
isolate, NCBI acc.nr. AB038249). Raw sequence data from the
454 sequencing experiments have been submitted to the SRA
database (accession number SRP023493).
454 sequencing: assay performance and criteria set. To
demonstrate the sensitivity and reliability of our 454 sequencing
approach several control samples were included in the study
design. Plasmid DNA carrying the archetype JC virus NCCR
(NCBI AB038249) was used as template for PCR (,100 000
calculated input copies) which allowed to evaluate for possible
errors that can be introduced during the amplification step as well
as 454 sequencing errors. To minimize this error rate all PCRs
were performed in triplicate, and triplicates were pooled
afterwards. Sensitivity of the assay was examined by spiking in a
similar plasmid DNA, but harboring a predefined 66 base pair
deletion at different ratios (i.e. 10%, 3%, 1% and 0.3%,
respectively) before PCR. A considerable number of non-genuine
DNA variations (i.e. deletions, insertions and single nucleotide
variations) were present in less than 1% of the analyzed sequences
retrieved for the control samples (data not shown) which is
generally considered as background variation in 454 sequencing.
To clean up our data and to increase reliability of the DNA
variations observed, three criteria were set to evaluate potential
DNA variations: 1) the background error rate was set at 1%
meaning that only DNA variations detected in at least 1% of the
viral sequences within a given sample are kept, 2) such variations
should be detected by both forward and reverse sequenced DNA
molecules at 1% and 3) DNA variations at homopolymeric DNA
motifs cannot be reliably interpreted. The control samples in
which the predefined 66 bp deletion was spiked in before PCR
could be accurately detected down to the level of ,1% while no
other false deletions and/or single nucleotide variations were
observed. From the control experiments it was concluded that our
approach was reliable.
Nested PCR for validation of deletions in JC virus NCCR
DNA
Viral DNA was extracted from urine samples of HS6 and HS11
as described above. Of note, HS11 was one of the healthy subjects
that donated several consecutive urine samples within a time
interval of ,1 year [at time point T0 (base line), T1 (,7 months
later), T2 (,8 months later) and T3 (,9.5 months later)]. First,
outer PCR was performed on viral DNA using the same primers as
for Sanger sequencing. A PCR pre-mix was prepared: 10 ml of
Phusion high fidelity master mix (26) (New England Biolabs), 1 ml
forward primer (10 mM), 1 ml reverse primer (10 mM) and 3 ml of
PCR-grade water. 5 ml of viral DNA was added as template and
PCR was run: 98uC for 30 seconds followed by 40 cycles of 98uC
for 10 sec, 60uC for 20 sec and 72uC for 20 sec and a final step at
72uC for 5 min. The outer PCR product was diluted 1:100 in
distilled water and used as template for two separate inner PCRs:
one using the primers Fwdb (59 aaggtagggaggagctg 39) and Revb
(59 cccttgtgctaggggtt 39) and one using the primers Fwdb and
Rev2b (59 cccttgtgctttgtttactt 39). Inner PCRs were run as follows:
98uC for 30 seconds followed by 30 cycles of 98uC for 10 sec,
60uC for 15 sec and 72uC for 15 sec and a final step at 72uC for
5 min. DNA amplicons were analyzed on pre-stained agarose gels
(4% e-gel, Invitrogen).
One ml of viral DNA from urine of HS53 was used in an outer
PCR as described above. 1:100 diluted PCR product was used as
template for two inner PCRs with primers Fwdb (59 aaggtagg-
gaggagctg 39) and Rev (59 tatgggaggggtttcact 39) or with primers
Fwdb and Rev (59 tatgggaggggcagtg 39), respectively. Cycling
conditions were: 98uC for 30 seconds followed by 30 cycles of
98uC for 10 sec, 70uC for 15 sec and 72uC for 15 sec and a final
step at 72uC for 5 min. DNA amplicons were analyzed on pre-
stained agarose gels (4% e-gel, Invitrogen).
Results
Sanger sequencing of the JC virus NCCR and VP1 coding
sequence
An overview of the experimental set up is given in Figure 1.
Urine samples were donated by 254 HSs. All samples were
screened for the presence of JC virus DNA by quantitative PCR.
JC Virus Quasispecies in Urine
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63 out of 254 HSs (,24.8%) had shed viral DNA into their urine.
A median of 6.60 log copies/ml (range 2.18–7.93) viral load (VL)
was determined for these samples. Two ml of extracted viral DNA
was used as template for Sanger sequencing of the NCCR.
Detailed NCCR sequence information for those samples deviating
from the archetype sequence by means of deletions and/or
insertions is available in Figure S1. Two samples failed during the
procedure likely due to their relatively low VL (2.18 and 2.27 log
copies/ml, respectively). In 15 out of 61 samples (,24.6%) small
deletions between 1 and 28 bp were identified in the NCCR while
insertions (duplications of 8 and 14 bp, respectively) were present
in only two samples (3.3%). One of these duplications was assigned
to a sample that also harbored a deletion in the NCCR (HS33,
Table 1). Relatively few single nucleotide changes were identified
in the NCCR. Only at 6 different positions a single nucleotide
variation was present compared to the Japanese CY isolate
archetype reference and this variation was mostly restricted to one
or two samples. One exception was at nucleotide position 217
where most samples deviated from the reference sequence (217-A
instead of 217-G). This nucleotide change has previously been
shown to be a common feature of European and Asian JCV strains
[23,27].
Based on the obtained full length VP1 coding sequences
(1065bp) phylogenetic analysis was performed to assign a JCV
genotype to the different samples (Figure 2). To build this tree
reference genotype sequences were used as described in [26]. Most
of the samples were divided over genotype 1, 2 and 4 while 2
samples clustered together with genotype 7 and no obvious
genotype 3 nor genotype 6 samples were present. Eleven out of the
fifteen samples carrying a polymorphic deletion in the consensus
NCCR were related to genotype 2 JCV while 2 of those samples
were genotype 7. The remaining samples were genotype 1 and 4,
respectively. Both samples harboring a duplication belonged to
genotypes 2 and 4 (Figure 2).
Identification of JC virus NCCR quasispecies in urine of
healthy subjects
For a total of 54 urine JCV DNA samples an interpretable 454
amplicon sequencing was obtained. Two ml of viral DNA (with
variable viral load) was used as template for PCR (performed in
triplicate) which implies that at least,4789 input copies were used
for 454 sequencing (Min: 4789; Max: 19,060,878; Mean:
3,013,724; and Median: 1,358,573) (Table S1). A total of
187,420 quality checked DNA sequences covering the full length
JCV NCCR were retrieved and divided over 59 samples (i.e. 54
urine samples and 5 plasmid control samples, see Materials and
Methods) resulting in an average coverage depth between 1,457
(min.) and 7,0446 (max.) per nucleotide position. Due to the
relatively high viral load for most of the urine samples, no
oversampling (i.e. sequencing the same DNA molecule multiple
times) occurred. Hence, no sequencing bias was introduced in our
data set (Table S1).
For all samples run in the 454 sequencing protocol obtained full
length NCCR DNA sequences were mapped against the archetype
reference sequence. The number of reads retrieved for each
sample is given in Table S1. This approach allowed deducing the
consensus NCCR sequence for all analyzed samples, which
represents the most abundant viral species (NCCR sequence)
present in a given sample. Importantly, all polymorphic deletions
and insertions as they were identified by Sanger sequencing were
recovered in these consensus sequences. Beyond the identification
of the NCCR consensus sequence, our main goal was to
investigate the presence of JCV quasispecies i.e. the identification
of additional viral variants within a single sample present at a
lower frequency than the consensus NCCR sequence (further
referred to as minority viral species). Therefore, for each sample all
retrieved NCCR sequences deviating from the reference sequence
were analyzed under the criteria set for sensitivity and reliability of
our assay (see Materials and Methods). Hence, only DNA
variations present in at least 1% of the total number of assigned
sequences and supported by both forward and reverse sequencing
were considered genuine variations. Overall, after analysis of the
454 sequencing data 4 samples out of 54 (7.4%) were identified as
containing quasispecies (Figure 1 and Table 1). Two out of 40 HS
without any rearrangements in the consensus NCCR carried
deletions present in 2% (HS26, 46 y old women) and 6.5% (HS53,
48 y old women) of the viral sequences, respectively. Both HS had
a high JCV VL of 7.3 and 6.1 log copies/ml urine, respectively. In
addition, 2 out of 12 HS harboring a deletion in the consensus
NCCR contained quasispecies (HS11; a 53 y old man with a VL
of 6.6 log copies/ml and HS45; a 60 y old women with a VL of
7.2 log copies/ml). Of note, for HS11 multiple consecutive urine
samples were collected in which persistent viral shedding was
found (see also below). No NCCR quasispecies were identified in
both samples carrying a DNA duplication in the consensus non-
coding control region (Table 1; HS46 and HS33). Three out of
four samples with assigned quasispecies harbored a deletion
present in only a minority of sequences. In one of these samples
the 1 bp deletion identified by Sanger sequencing (HS11, del 165,
Table 1) was part of the larger deletion (del162–189) identified as
minor virus variant in this sample. Of interest, sample HS45 was
peculiar since a relatively large 28 bp deletion was identified in
95% of all analyzed sequences after mapping against the reference
sequence. Hence, still ,5% of the NCCR sequences obtained for
this sample perfectly matched when compared with the reference
archetype sequence.
Next to DNA rearrangements, the intra-sample single nucleo-
tide variability was also investigated by 454 sequencing in search
for potential quasispecies characterized by nucleotide replace-
ments. When applying our stringency settings to evaluate the
presence of genuine DNA variations single nucleotide replace-
ments could not be identified in any of the samples. Hence, it
appeared that no minority viral variants characterized by specific
nucleotide replacements were present in the 54 urine samples
analyzed by next generation sequencing.
Validation of JC virus quasispecies identification in urine
of healthy subjects
In order to validate the presence of JC virus quasispecies in
HS11 (i.e. a 28 bp deletion present in ,1.5% of the viral DNA
sequences, Table 1) a nested PCR approach was followed. Viral
DNA was freshly prepared from the following urine samples:
HS11 T0 (viral load 7.3 log copies/ml), HS11 T1 (i.e. the urine
collection also used for 454 sequencing; viral load 6.6 log copies/
ml), HS11 T2 (viral load 7.8 log copies/ml) and HS11 T3 (viral
load 7.7 log copies/ml) which gave the opportunity to follow the
presence of the detected deletion over time. A nested PCR
approach was applied on these samples as described under
Methods and graphically explained in Figure 3A. As a negative
control, viral DNA extracted from HS6 and in which the 28 bps
deletion was not detected by 454 sequencing, was included in the
assay. As expected a JC virus NCCR DNA fragment was amplified
during inner PCR when primers designed to target a consensus
fragment, present in both HS6 and HS11, were used (Figure 3B;
upper panel). However, only in sample HS11 T1 a DNA fragment
was successfully amplified during inner PCR in which the
consensus reverse primer was replaced with a primer over-
spanning the potential deletion (Figure 3B; lower panel). This
JC Virus Quasispecies in Urine
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result confirms that the quasispecies detected in HS11 truly exists
and can be specifically attributed to this sample, but in this case is
likely to be a transient phenomenon as it was not detected in later
samples. Using a similar nested PCR approach the 15 bp deletion
identified in ,6.5% of the DNA sequences from HS53 (Table 1)
were also confirmed to be genuine and specific for HS53
(Figure 3C).
Discussion
The non-coding control region interspersed between early and
late coding genes on the JC virus genome is known to play a
pivotal role in viral replication by regulating early gene expression
and by being susceptible to host transcription factors [15,17,24].
DNA rearrangements within this region are strongly linked with
PML indicating that the NCCR might be a viral determinant
supporting viral growth in infected glial cells. In line with this view,
several reports have demonstrated increased in vitro early gene
transcription and viral replication driven by naturally occurring
rearranged JCV NCCR sequences taken from PML-cases [17,22].
Whether such rearrangements emerge and out-compete archetype
NCCR during PML progression or, alternatively, if PML is caused
by infection of glial cells with pre-existing rearranged JC virus, are
still a matter of debate. We reasoned that when rearrangements in
the NCCR would occur within an infected host (i.e. if JCV
quasispecies would exist) this might add to the risk of changing
viral tropism, for instance due to an altered sensitivity of the
NCCR for cell-specific transcription factors. Therefore, the
rationale of this study was to examine to what extent variation
in the NCCR and NCCR quasispecies occur within healthy
subjects. For this, HSs were selected based on the presence of viral
DNA in their urine. Since viral DNA present in urine is likely to be
Figure 1. Outline of the experimental work presented. JC virus DNA was detected in urine of 63 out of 254 healthy subjects (HSs) by qPCR
targeting the large T antigen (LTAg) gene. For 61 viral shedders the full length VP1 coding sequence and the non-coding control region (NCCR) DNA
was obtained via Sanger sequencing. When compared to a reference archetype NCCR (i.e. CY isolate, NCBI acc.nr. AB038249) 44 samples did not
contain any rearrangement while 15 samples (24.6%) harbored a deletion (between 1 and 28 bp), 1 sample (1.6%) carried a duplication in the
consensus NCCR sequence and 1 sample carried both an insert and a deletion. A subset of 54 urine JCV DNA samples were further analyzed by next
generation sequencing (454 pyrosequencing) to specifically look at the presence of JCV quasispecies that were identified in 2 out of 40 archetype
samples (5.0%) and 2 out of 12 samples (16.6%) that contained a deletion when analyzed by Sanger sequencing. No quasispecies were detected in
both samples carrying a duplication in the consensus NCCR.
doi:10.1371/journal.pone.0070950.g001
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a transmittable form of JCV [18,28] studying NCCR rearrange-
ments seems also of particular interest here.
Our scope was not limited to study the variation observed in the
consensus NCCR sequences, which has been addressed previously
in different cohorts by Sanger sequencing [23,29,30], but was
mainly focused on investigating quasispecies present in the host by
applying next generation sequencing. Due to its ability to generate
relatively long DNA sequences, a crucial feature to reliably detect
insertions and deletions within a DNA sequence, 454 (pyro)-
sequencing was the platform of choice. Stringent criteria were set
for analysis purposes to demonstrate the sensitivity and reliability
of the assay allowing the detection of NCCR variability even if it
was present in only a minor fraction of the sequenced viral
population. No common genomic alterations were identified in the
minority viral species contributing to the quasispecies (Table 1).
However, a main feature of most of the genomic alterations, both
defining the consensus NCCR as well as the minority viral species,
was the deletion of part of the NCCR. Our data seem to be in line
with a current notion that deletions precede duplication events
during the NCCR rearrangement process [31] as has been
previously suggested for PML-associated JCV [21].
Our observations might shed some light on the molecular
evolution of JC virus within a naturally infected host. It has been
suggested previously that during the course of JC virus evolution
sporadic genomic rearrangements in the NCCR occur and might
ultimately become dominant over the archetype in some JCV
lineages or sub-lineages [23]. The presence of a unique, sporadic
JCV NCCR rearrangement characterized by a 36 nucleotide
insertion unrelated to the genomic alterations presented in this
manuscript, and previously reported to be present in the urine of a
healthy donor [30] can be readily explained in a similar way. The
polymorphic deletions and insertions identified in ,28% of the
analyzed samples (Figure 1) in our sample set seem to further
support this idea. If assumed that the archetype NCCR represents
an ancient form of JC virus from which all rearranged forms are
derived [19,28], any deletion and/or insertion that goes along with
more efficient viral replication (e.g. via enhancing transcription of
LTAg) might become positively selected within a specific cellular
context, likely due to the loss of negative or the creation of positive
transcriptional control signals [17,22]. Although we cannot
discriminate between scenarios in which the polymorphic rear-
rangements identified in HSs resulted from an intra-host natural
selection or were the consequence of an infection with a pre-
existing rearranged JCV strain, the observation made in one of our
samples seems to be in favor of the first possibility. As shown, one
of the HSs was characterized as a viral shedder in which ,95% of
the NCCR DNA copies shed into the urine carried a 28 base pairs
deletion (Table 1), implying that ,5% of the JC virus DNA still
matched with the archetype reference sequence. Therefore, it
seems likely that this specific rearrangement indeed has become
positively selected and might potentially out-compete the non-
rearranged archetype form. Similar observations were made in
plasma from immune suppressed kidney transplant patients where
rearranged BKV NCCR variants emerged and replaced the
archetype BKV as majority (consensus) species in vivo during
persistent viremia [32]. Assuming that JCV present in urine is an
infectious and transmittable form [28], such sporadic rearrange-
ment might have the potential to start spreading and circulating
within a human population, providing a possible explanation for
observations made by others [23,29].
Another interesting observation came from HS11 in which a 28
base pairs deletion was identified in ,1.5% of the viral population
Table 1. Overview of JC virus NCCR rearrangements (i.e. deletions and insertions) identified by Sanger sequencing and 454
sequencing.
NCCR consensus Quasispecies
Sanger sequencing 454 sequencing
(n = 61) (n=54)
sample rearrangement sample minority species
1. archetype All, except under 2, 3 and 4 none HS26 del 160 (,2%;d)
(n = 44) HS53 del 142–156 (,6,5%; d)
2. deletions HS11, HS37, HS40,HS55,HS61 del 165 (d) HS11 del 162–189 (,1,5%; d–e)
(n = 15) HS20 del 126–153 (d)
HS31 del 106–116 (c–d)
HS7, HS9 del 218–222 (f)
HS5, HS23, HS43, HS51, HS57 del 221–222 (f)
HS45 del 216–243 (f) HS45 archetype (,5%)
3. insertions HS46 ins 216–14bp (f)
(n = 1)
4. insertion +
deletion
HS33 ins 74–8bp (c) + del 221–222 (f) none
(n = 1)
Comparison of the consensus NCCR as determined by Sanger sequencing (n = 61) revealed four distinct groups of samples: 1) archetype sequences with no DNA
rearrangements compared to the reference NCCR (CY isolate), 2) samples harboring polymorphic deletions, 3) samples carrying polymorphic insertions and 4) sample
harboring both a deletion and an insertion. 454 sequencing was further applied (n = 54) to identify JCV quasispecies. Healthy subject (HS) samples in which quasispecies
were identified, the nature of the minority sequences contributing to the quasispecies and the percentage of viral NCCR sequences harboring the minority sequences
are indicated. The sequence blocks (a to f) affected by the NCCR rearrangements are indicated between brackets. Of note, HS11 carries a 1 bp deletion at position 165
that in ,1.5% of the viral population is part of a more extensive deletion. The numbering scheme is based on [12].
doi:10.1371/journal.pone.0070950.t001
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isolated from urine at a given time point (T1). By applying a nested
PCR approach we showed that this particular variant was
genuine, but cleared from the viral population (or at least became
undetectable in our assay), by a yet unknown mechanism, about
1 month later (at time point T2 and in subsequent samples). It has
been hypothesized before that most alterations in the JCV NCCR
need to be categorized as ‘‘dead end’’ meaning that they are only
transiently present in the viral population [18]. Mechanisms by
why some NCCR rearrangements become positively selected
while others are cleared from the population are yet to be fully
understood. A concerted interplay of viral determinants, host cell
factors and antiviral immune responses is likely to add to this
selection. Evidently, if the NCCR deletion specified here for HS11
would cause suppressed viral replication compared to the
archetype JCV it would be expected to ultimately disappear.
Most NCCR rearrangements studied so far, both for JCV and
BKV and including even relatively modest alterations (i.e. single
deletions or duplications) were shown to significantly increase early
gene transcription and replication in a variety of cell lines
[17,22,32,33]. It should be noted however, that most of these
sequences originated from patient samples (i.e. JCV PML cases,
BKV kidney transplant recipients) creating a bias towards positive
selection of highly replicating rearranged viral strains. Hence, non-
functional, negatively selected NCCR sequences are less likely to
be identified, but nevertheless likely to exist. Even more, the
relatively low number of JCV quasispecies identified by 454
sequencing might be an underestimation of the true susceptibility
of the NCCR for genomic rearrangements due to the transient
nature of most of the emerging viral quasispecies. Also the cellular
environment in which virus replication takes place is likely to be an
Figure 2. Phylogenetic analysis based on the VP1 coding sequence from healthy subjects. The full length VP1 coding sequence (1065 bp)
was obtained for all healthy subjects for which also the non-coding control region (NCCR) was Sanger sequenced (n = 61). The relatedness of the HS
samples to defined JC virus genotypes is illustrated in a phylogenetic tree. For each JCV genotype the following reference VP1 coding sequences
were used (NCBI accession number between brackets; reference sequences taken from [26]): genotype 1A (AF015526), genotype 1B (AF015527),
genotype 2A (AF015529), genotype 2B (AF015533), genotype 2C (AF015535), genotype 2D (AF015536), genotype 2E (AF281606), genotype 3A
(U73500), genotype 3B (U73501), genotype 4 (AF015528), genotype 6 (AF015537), genotype 7 (U61771). Healthy subjects (HS) in which deletions or
insertions were identified in the non-coding control region via Sanger sequencing are indicated by * (deletion) or + (insertion). HSs in which JCV
quasispecies were identified by 454 sequencing are circled.
doi:10.1371/journal.pone.0070950.g002
Figure 3. Validation of JC virus quasispecies by nested PCR. (A) A nested PCR approach was developed to validate the presence of the 28 bps
deletion identified in ,1.5% of the viral DNA sequences in HS11. (B) The nested PCR approach was applied on viral DNA extracted from urine from
HS11. Urine aliquots donated at different time points were included: T0, T1, T2 and T3. Viral DNA extracted from HS6 T1 was included as a negative
control, together with a no template control (NTC). The upper panel shows successful amplification of the consensus DNA fragment in all samples. In
contrast, only in HS11 T1 a PCR fragment could be amplified when using the reverse primer spanning the deletion instead of the consensus reverse
primer, confirming the presence of this deletion. L = 25 base pair DNA ladder (Invitrogen). (C) A similar nested PCR approach was used to demonstrate
the existence of quasispecies in HS53. DNA fragments were generated when a primer set designed to amplify a consensus sequence from both HS53
and HS26 (lanes HS53 con and HS26 con) were used. When the reverse primer was replaced by a primer specifically targeting the sequence deleted in
the quasispecies succesfull amplification was only detected in HS53 (HS53 del), but not in HS26 (HS26 del). NTC: no template control. L = 25 base pair
DNA ladder (Invitrogen).
doi:10.1371/journal.pone.0070950.g003
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additional feature driving quasispecies emergence. Whereas JCV
replication is dependent on host cell DNA polymerase and, hence,
occurs at high fidelity in most permissive cell types, the DNA
recombination apparatus present in B-lymphocytes might support
rearrangement of the NCCR [31] potentially rendering them
more prone to quasispecies detection.
Host antiviral immunity might also participate in controlling
viral quasispecies [32]. An interesting concept was put forward
stating that cellular immunity directed against early gene encoded
epitopes may contribute in controlling the emergence of
rearranged, highly replicating BKV in healthy immune competent
individuals [32], possibly reflective of the relatively low number of
quasispecies identified in our group of healthy subjects. Under
conditions of immune suppression however, impaired T-cell
activity might facilitate the emergence of rearranged BKV as
shown for immune suppressed kidney transplant patients [32]. If
such scenario holds true it merits further investigation to
determine if intra-host born JCV NCCR rearrangements are
more likely to happen in immune suppressed individuals
compared to healthy subjects.
JC virus is the causative agent for PML. Although viral
determinants contributing to the pathogenesis of PML remain
poorly understood special interest has been paid to be the so-called
domain d of the NCCR which turns out to frequently carry
deletions in PML-associated samples [2,17,21]. In addition, in vitro
cell assays also underline the importance of NCCR domain d in JC
virus replication [17]. Of note, some of the deletions that we
identified here are also located in or near domain d whereas the
ori-proximal end of the NCCR turned out to be less prone to
rearrangements. In addition to domain d also domain f was shown
to be highly affected by deletion events (Table 1). Multiple studies
have indicated that the JCV NCCR harbors various transcription
factor binding sites, amongst which recognition sites for the NFI
family of cellular DNA binding proteins, SP1, SPi-B, Tst-1/Oct-
6/SCIP and AP-1 (c-jun) are located within domain d and f (see
[18] and references therein for a comprehensive review on host
transcription factors influencing JCV transcription). Clearly,
rearrangements in this region might alter the binding capacity of
the host transcription factors adding to changed viral tropism and
altered gene transcription levels, a hypothesis that merits further
investigation.
In conclusion, we investigated the presence of JC virus
quasispecies in urine of healthy subjects and were able to
demonstrate their existence in a minor part of the study population
(,7.4%). Taken together, from our work the idea emerges that the
occurrence of DNA variability in the NCCR of JCV is a dynamic
process with specific rearrangements becoming positively selected,
while other variations are likely to be only transient. Whether these
naturally occurring variants can alter the viral tropism and to what
extent they might add to an increased risk for PML following
opportunistic infection of the brain remains to be examined.
Nevertheless our experimental approach turns out to be a valuable
tool readily applicable for future investigations of JCV quasispecies
in other cellular reservoirs or body fluids and under relevant
clinical settings such as immune suppression.
Supporting Information
Figure S1 Sequence alignment of the non-coding control
region DNA sequence retrieved by Sanger sequencing
from viral DNA isolated from urine (n=17). Only samples
in which DNA rearrangements (deletions or insertions) were
identified in comparison to the archetype reference sequence are
included in the alignment. DNA regions in which no rearrange-
ments were present are not shown and are symbolized by//. On
top of the alignment the archetype (AR) NCCR from CY isolate
(267 nucleotides, NCBI acc.nr. AB038249) is presented. Deletions
are indicated by *. Gaps (2) were introduced for proper alignment
of the sequences. Single nucleotide changes (compared to the
reference sequence) are shaded in grey. Nucleotide numbering of
the NCCR is indicated on top of the alignment. The lower bar
gives a schematic representation of the NCCR DNA architecture
[18] showing in which predefined NCCR domain the identified
rearrangements were present. Ori: origin of replication.
(TIF)
Table S1 Viral load and input copy number for urine
samples analyzed by 454 sequencing. Viral DNA was
extracted from urine samples from HSs and used as template for
PCR and subsequent 454 sequencing as described under Methods.
All samples were assigned a multiplex identifier (MID; see
Materials and Methods) for analysis purposes. In total 187,420
DNA sequences (reads) covering the full length JCV NCCR were
retrieved and mapped on the reference sequence (i.e. JCV NCCR
archetype sequence, CY isolate, from NCBI accession number
AB038249). The number of analyzed reads per urine sample is
indicated. The JC virus viral load (JCV VL) as determined for the
urine samples is expressed as log copies/ml. Based on this VL a
sampling size i.e. number of analyzed reads divided by the input
copy number was calculated.
(XLS)
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